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Serotonin toxicity (ST) is a rare clinical state, which 
may be serious and life‑threatening. The most common 
reasons are usage of multiple serotonergic drugs 
together or combination of one serotonergic agent and 
one monoamine oxidase (MAO) inhibitor. Isoniazid 
(INH) is a weak MAO inhibitor[1] and also may affect 
cytocrome enzyme system.[2] So, it may interact with 
serotenergic agents like essitalopram.[3] ST due to 
combination of isoniazidand essitalopram was rarely 
reported before.[3] To suspect from the state and history 
of serotonergic drug usage are main factors for diagnosis.
Although clinical signs of ST on nervous system are 
well‑known, no specific electrophysiological finding was 
demonstrated before. Here, we report a case of serotonin 
toxicity due to the combination of essitalopram and 
isoniazid. We also observed transient electromyographic 
findings, which may probably be due to serotonergic 
activity.
Case Report
A Forty‑three‑years‑old female developed acute onset 
fever and confusion. She was receiving corticosteroids 
with the diagnosis of Takayasu arteritis for the recent 
three years. She was also taking isoniazid cause of a 
suspicious positive result in tuberculin skin test (PPD) 
for the last three months.
Neurological examination revealed fever, rigidity, 
clonus, bilateral positive Babinsky and Hoffman signs, 
and hyperactive deep tendon reflexes. Cranial and 
spinal magnetic resonance imaging (MRI) showed no 
abnormalities nor contrast enhancement. Nerve conduction 
studies were normal, but needle electromyography 
(EMG) demonstrated spontaneous neurogenic changes 
(fibrillation and positive waves) in her extensor digitorum 
brevis (EDB), tibialis anterior (TA), and gastrocnemius 
muscles. There were no chronic neurogenic signs.
Further investigations for toxic, nutritional, and 
infectious spinal cord diseases revealed nothing.
We learned that she had been taking essitalopram 20 mg/
day for last month from her relatives.
With the help of this medical history, she was diagnosed 
as serotonergic toxicity, essitalopram was stopped, and 
the patient was hydrated. In her follow‑up, she started 
to get better on the third day of drug‑free period. After 




Here, we report a case of serotonergic toxicity due to combination of essitalopram and isoniazid, which was rarely 
reported before. Moreover, we observed transient neurogenic denervation potentials in needle electromyography, 
which disappeared with the treatment of serotonergic toxicity. As to our best knowledge, this is the first case, reporting 
transient electromyographic changes probably due to serotonergic toxicity.
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one week, she was completely improved. No rigidity, 
clonus, or pyramidal sign was detected. Repeated EMG 
was completely normal.
Discussion
Nowadays, the term serotonin toxicity (ST) is often 
referred to serotonin syndrome (SS).[4] There is no 
specific laboratory or diagnostic test, so the diagnosis 
is mostly based on the clinical aspects.[5] A history of 
serotonergic agent or increment in the dosage, four 
major or three major + two minor symptoms, exclusion 
of psychiatric, toxic, metabolic and endocrine diseases, 
and neuroleptic usage were needed for diagnosis.[6] Our 
case fulfilled all criteria and revealed six major symptoms 
like myoclonus, tremor, rigidity, hyperreflexia, fever, and 
confusion. Although citalopram is widely used because 
of its favorable safety profile and lack of cytochrome 
P450 inhibition,[7] it has been reported to cause serotonin 
toxicity, usually in the setting of an overdose.[8,9] 
Citalopram is a substrate for CYP2C19 and 3A4, and 
isoniazide may inhibit cytochrome P450 (CYP450) 
isoforms, potent inhibition of CYP2C19 and CYP3A.[2] INH 
is also a MAO inhibitor,[1] so may affect the metabolism 
of anti‑depressant drugs. INH plus essitalopram was 
rarely reported to be the cause of serotonergic toxicity.[3] 
There are no prospective treatment studies for serotonin 
toxicity. General management measures include removal 
of the precipitating serotonergic agent and supportive 
strategies to control the state.[10] In our case, general 
supportive treatment to stop essitalopram improved 
the clinical symptoms and signs of the patient. SS is a 
generalized toxic syndrome; therefore, both cognitive 
and neuromuscular findings may be observed. But, in 
most of the cases, clinical symptoms are more prominent 
in lower and distal part of extremities, which also may 
be a clue for a spinal process. As to our best knowledge, 
there is no specific electrophysiological finding of SS in 
the literature. The spontaneous denervation potentials 
that we observed during the etiological investigations 
of the patient may be due to a coincidental disease. 
Nerve conduction studies were normal while there were 
acute denervation potentials, which lead to the idea of a 
pathology located more proximal to spinal ganglia. But, 
there were no abnormalities or contrast enhancement in 
her spinal MRI. Moreover, disappearance of spontaneous 
denervation potentials after treatment of serotonergic 
syndrome would be an evidence for toxic effects of 
serotonin on spinal cord cells. As a result, usage of INH 
inhibited the metabolism of serotonin and induced 
serotonergic toxicity in our case. Interaction of INH and 
essitalopram was rarely reported before; however, our 
case is the first to report probable electrophysiological 
findings due to serotonergic toxicity.
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